Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -0.03% |
| Q2 2025 | 5.37% |
| Q1 2025 | -67.14% |
| Q4 2024 | -9.42% |
| Q3 2024 | 4.03% |
| Q2 2024 | -1.81% |
| Q1 2024 | 2.58% |
| Q4 2023 | -15.06% |
| Q3 2023 | 65.44% |
| Q2 2023 | -14.12% |
| Q1 2023 | 176.52% |
| Q4 2022 | -310.05% |
| Q3 2022 | -76.02% |
| Q2 2022 | 628.68% |
| Q1 2022 | 9.72% |
| Q4 2021 | 25.46% |
| Q3 2021 | -21.38% |
| Q2 2021 | 25.74% |
| Q1 2021 | -25.83% |
| Q4 2020 | 78.70% |
| Q3 2020 | -12.54% |
| Q2 2020 | -8.09% |
| Q1 2020 | -13.75% |
| Q4 2019 | -31.83% |
| Q3 2019 | -24.71% |
| Q2 2019 | -43.70% |
| Q1 2019 | 35.33% |
| Q4 2018 | -52.71% |
| Q3 2018 | 27.10% |
| Q2 2018 | -9.87% |
| Q1 2018 | 110.21% |
| Q4 2017 | -12.03% |
| Q3 2017 | 35.33% |
| Q2 2017 | 13.03% |
| Q1 2017 | -48.40% |
| Q4 2016 | 85.98% |
| Q3 2016 | -14.05% |
| Q2 2016 | 54.24% |
| Q1 2016 | -31.42% |
| Q4 2015 | 8.96% |